Pink Sheet Podcast: Regeneron’s COVID Monoclonal Deal, New FDA Advisor, Project Optimus In Cancer Combos
Pink Sheet reporter and editors discuss the somewhat novel pricing language in Regeneron’s deal with the US government to develop a COVID-19 monoclonal antibody, US FDA Commissioner Robert Califf hiring a new senior advisor, and optimizing dosing in cancer combination therapies.
You may also be interested in...
Litany of deficiencies, including product quality shortcomings and a failed Phase III clinical efficacy study, may make it impossible for the agency to exercise the type of flexibility it has with the approval of other treatments for ALS and neurodegenerative diseases.
Arizona State University neural transplantation expert Jeffrey Kordower said FDA requested he not participate in the advisory committee because of his relationship with sponsor BrainStorm. Kordower says a 2022 journal article erroneously stated he had an ownership interest in the company.
After years where many more applications received priority assessments than standard assessments, in FY 2022 the difference narrowed.